Literature DB >> 7597664

An alternative aerosol delivery system for amiloride.

M L Everard1, S G Devadason, V B Sunderland, P N Le Souef.   

Abstract

BACKGROUND: The advent of novel treatments such as aerosolized amiloride are potentially useful additions to the therapeutic options available for the treatment of cystic fibrosis. Unfortunately, amiloride and other aerosolized drugs such as antibiotics are generally administered via jet nebulisers which are time consuming to use, and thus limit the acceptance and efficacy of these forms of treatment. In vitro experiments were performed in order to determine whether amiloride could be administered in dry powder form using a Turbohaler.
METHODS: Amiloride was micronised and loaded into 200 micrograms Turbohalers. The dose delivered per actuation and particle size distribution of the generated aerosol were assessed using a flow of 60 l/min through the Turbohaler. The dose of amiloride delivered was measured by collecting the aerosol on a filter and the quantity of drug was assayed by an ultraviolet spectrophotometric method. The particle size distribution was assessed using a Malvern MasterSizer laser particle sizer and compared with that generated by a commercially available 200 micrograms budesonide Turbohaler.
RESULTS: The mean (SD) dose delivered per actuation was 246.3 (40.4) micrograms. The volume median diameter of the amiloride aerosol was 3.80 (0.68) micron compared with 3.07 (1.47) microns for budesonide.
CONCLUSIONS: These results suggest that therapeutic doses of micronised amiloride could be delivered effectively and conveniently as a dry powder aerosol using a Turbohaler.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7597664      PMCID: PMC1021221          DOI: 10.1136/thx.50.5.517

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  8 in total

1.  A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis.

Authors:  R C Hubbard; N G McElvaney; P Birrer; S Shak; W W Robinson; C Jolley; M Wu; M S Chernick; R G Crystal
Journal:  N Engl J Med       Date:  1992-03-19       Impact factor: 91.245

2.  Inhaled micronised gentamicin powder: a new delivery system.

Authors:  J M Goldman; S M Bayston; S O'Connor; R E Meigh
Journal:  Thorax       Date:  1990-12       Impact factor: 9.139

3.  Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy.

Authors:  E M App; M King; R Helfesrieder; D Köhler; H Matthys
Journal:  Am Rev Respir Dis       Date:  1990-03

4.  A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis.

Authors:  M R Knowles; N L Church; W E Waltner; J R Yankaskas; P Gilligan; M King; L J Edwards; R W Helms; R C Boucher
Journal:  N Engl J Med       Date:  1990-04-26       Impact factor: 91.245

5.  Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis.

Authors:  C Ranasinha; B Assoufi; S Shak; D Christiansen; H Fuchs; D Empey; D Geddes; M Hodson
Journal:  Lancet       Date:  1993-07-24       Impact factor: 79.321

6.  Amiloride inhalation therapy in cystic fibrosis. Influence on ion content, hydration, and rheology of sputum.

Authors:  R P Tomkiewicz; E M App; J G Zayas; O Ramirez; N Church; R C Boucher; M R Knowles; M King
Journal:  Am Rev Respir Dis       Date:  1993-10

7.  Pulmonary deposition of nebulised amiloride in cystic fibrosis: comparison of two nebulisers.

Authors:  S H Thomas; M J O'Doherty; A Graham; C J Page; P Blower; D M Geddes; T O Nunan
Journal:  Thorax       Date:  1991-10       Impact factor: 9.139

8.  Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects.

Authors:  L Borgström; E Bondesson; F Morén; E Trofast; S P Newman
Journal:  Eur Respir J       Date:  1994-01       Impact factor: 16.671

  8 in total
  3 in total

Review 1.  Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.

Authors:  Lauren Willis; Don Hayes; Heidi M Mansour
Journal:  Lung       Date:  2012-01-25       Impact factor: 2.584

2.  Characterisation of a carrier-free dry powder aerosol formulation using inertial impaction and laser diffraction.

Authors:  Gary P Martin; Helen B MacRitchie; Christopher Marriott; Xian-Ming Zeng
Journal:  Pharm Res       Date:  2006-08-10       Impact factor: 4.200

3.  Correlation between inertial impaction and laser diffraction sizing data for aerosolized carrier-based dry powder formulations.

Authors:  Xian-Ming Zeng; Helen B MacRitchie; Christopher Marriott; Gary P Martin
Journal:  Pharm Res       Date:  2006-08-10       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.